This is a summary of the European public assessment report (EPAR) for Skilarence. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Skilarence. For practical information about using Skilarence, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
Skilarence is indicated for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.
Therapeutic Area (MeSH)
ATC Code
L04AX07
ATC Item
N/A
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| dimethyl fumarate | N/A | dimethyl fumarate |
EMA Name
Skilarence
Medicine Name
Skilarence
Aliases
N/ANo risk management plan link.
